ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,672.09
      1.35%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. AbbVie Inc (ABBV)

      7. AbbVie Inc (ABBV) News

      ABBV

      AbbVie (ABBV)

      AbbVie Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:ABBV
      DateTimeSourceHeadlineSymbolCompany
      11/24/20227:01AMPR Newswire (Canada)The Impact of Inaction - New Publication Reveals Not All of Canada is on Track to Meet Global Hepatitis C Elimination GoalNYSE:ABBVAbbVie Inc
      11/23/20228:00AMPR Newswire (US)AbbVie to Present at the Evercore ISI HealthCONx ConferenceNYSE:ABBVAbbVie Inc
      11/23/20222:44AMDow Jones NewsTeva, Allergan Finalize Terms of Nationwide Opioid Settlement -- UpdateNYSE:ABBVAbbVie Inc
      11/23/20222:00AMPR Newswire (US)AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's DiseaseNYSE:ABBVAbbVie Inc
      11/22/20223:45PMPR Newswire (US)AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual MeetingNYSE:ABBVAbbVie Inc
      11/22/20229:00AMPR Newswire (US)AbbVie to Present at the Piper Sandler Healthcare ConferenceNYSE:ABBVAbbVie Inc
      11/21/20228:46AMDow Jones NewsAbbVie, Genmab Get FDA Priority Review of Epcoritamab in Large B-Cell LymphomaNYSE:ABBVAbbVie Inc
      11/21/20228:00AMPR Newswire (US)U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell LymphomaNYSE:ABBVAbbVie Inc
      11/17/20228:45AMPR Newswire (US)Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One YetNYSE:ABBVAbbVie Inc
      11/16/20229:00AMPR Newswire (Canada)Les personnes atteintes de migraine au Canada disposent d'une nouvelle option de traitement - Santé Canada approuve UBRELVY® (comprimés d'ubrogépant)NYSE:ABBVAbbVie Inc
      11/16/20229:00AMPR Newswire (Canada)Canadian Migraine Sufferers Have New Treatment Option - Health Canada Approves UBRELVY® (ubrogepant tablet)NYSE:ABBVAbbVie Inc
      11/14/20229:37PMTipRanksThe Top Dividend Stocks to Prepare for RetirementNYSE:ABBVAbbVie Inc
      11/09/20228:00AMPR Newswire (US)AbbVie to Present at the Wolfe Research Healthcare ConferenceNYSE:ABBVAbbVie Inc
      11/08/20223:06PMPR Newswire (US)AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022NYSE:ABBVAbbVie Inc
      11/07/202212:31PMPR Newswire (US)AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery PatientsNYSE:ABBVAbbVie Inc
      11/04/20221:09PMEdgar (US Regulatory)Quarterly Report (10-q)NYSE:ABBVAbbVie Inc
      11/03/20228:00AMPR Newswire (US)Allergan Aesthetics Reaffirms Commitment to Breast Health Advocacy with Yearlong Program for Breast Cancer AwarenessNYSE:ABBVAbbVie Inc
      11/02/20228:00AMPR Newswire (US)Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) DayNYSE:ABBVAbbVie Inc
      11/02/202212:45AMTipRanksSVB Securities Issues a Sell Rating on AbbVie (ABBV)NYSE:ABBVAbbVie Inc
      11/01/20223:10AMTipRanksAtlantic Equities Sticks to Its Hold Rating for AbbVie (ABBV)NYSE:ABBVAbbVie Inc
      11/01/20223:10AMTipRanksAbbVie (ABBV) Receives a Hold from BarclaysNYSE:ABBVAbbVie Inc
      11/01/20223:09AMTipRanksMorgan Stanley Sticks to Its Buy Rating for AbbVie (ABBV)NYSE:ABBVAbbVie Inc
      10/31/202210:12AMTipRanksAnalysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), AbbVie (ABBV)NYSE:ABBVAbbVie Inc
      10/28/20228:45AMPR Newswire (US)AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL)NYSE:ABBVAbbVie Inc
      10/28/20228:34AMDow Jones NewsAbbVie Boosts Quarterly Dividend by 5%NYSE:ABBVAbbVie Inc
      10/28/20227:44AMPR Newswire (US)AbbVie Reports Third-Quarter 2022 Financial ResultsNYSE:ABBVAbbVie Inc
      10/27/20229:40AMTipRanksAnalysts Offer Insights on Healthcare Companies: Bristol Myers (BMY) and AbbVie (ABBV)NYSE:ABBVAbbVie Inc
      10/24/20227:00AMPR Newswire (US)AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific MeetingNYSE:ABBVAbbVie Inc
      10/21/20225:30PMDow Jones NewsFDA Approves AbbVie's RINVOQ Therapy For Active Non-Radiographic Axial SpondyloarthritisNYSE:ABBVAbbVie Inc
      10/21/20224:42PMPR Newswire (US)RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA ApprovalNYSE:ABBVAbbVie Inc
       Showing the most relevant articles for your search:NYSE:ABBV